You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immunotherapy toxicities
654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors

https://doi.org/10.1136/jitc-2020-SITC2020.0654

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.